I am Professor and Director of the prolific and successful Neuromuscular Division at the University of Kansas Medical Center (KUMC). I am in charge of 2 fellowship programs in the Neurology Department and direct the educational curriculum associated with both Clinical Neurophysiology and Neuromuscular Medicine. I lead the Neuromuscular Clinic which coordinates the care of a large population of patients with muscle, nerve, neuromuscular junction and anterior horn cell disorders. I also serve on the Medical Advisory Board of The Myositis Association and Myasthenia Gravis Foundation of America. Since I joined the KUMC in 2007, I have been directly involved in all aspects, activities and processes relating to Neuromuscular research and the arimoclomol in IBM pilot study as well as the currently funded1RO1FD004809-01A2 multicenter international randomized controlled trial investigating the efficacy and safety of Arimoclomol in IBM. I am the director of the Neuromuscular Research Center at the KUMC-Neurology Department and Associate Director of the Institute for Neurologic Discoveries. I am also involved in a variety of federally-funded neuromuscular research projects as well pharma-sponsored studies, nationally and internationally. I also have leadership experience in maintaining large volumes of studies that require a great deal of communication among team members, and I am well trained in regulatory compliance requirements. I am the overall sponsor and study PI for a multicenter North American study of SCIg in myasthenia gravis funded by CSL-Behring. I currently serve since 2013 as Associate Director for the KUMC NeuroNext site, named Heartland Unit for Neuroscience Trials (HUNT). I have participated in trials in myopathies for many years and have research experience in a broad range of neuromuscular disorders including myasthenia gravis, neuropathy and ALS.
Bibliography link to pub med of my 112 publications https://www.ncbi.nlm.nih.gov/pubmed/?term=dimachkie+m